Status:
TERMINATED
Effects of Omega-3 Docosapentaenoic Acid on Lipids and Other Risk Factors for Cardiovascular Disease
Lead Sponsor:
University of Arizona
Conditions:
Elevated Triglycerides
Cardiovascular Risk Factor
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Elevated plasma triglycerides (TG) are due to an excess of TG-rich lipoproteins of several different types, most commonly of very-low-density lipoproteins (VLDL), but also intermediate-density lipopro...
Detailed Description
This is a cross-over, double-blind, randomized, placebo-controlled clinical study. Each treatment phase will span a continuous 6-week period. Prior to the first treatment phase, participants will be a...
Eligibility Criteria
Inclusion
- Elevated fasting TG (150-500 mg/dL)
- BMI of 18-40 kg/m2
- Consistent dosage for any medication/supplements taken for elevated lipids, blood pressure, glucose, or inflammatory conditions
- Ability to abstain from alcohol for 48 hours prior to lab testing
- Low fish consumption (\<2 servings/week)
Exclusion
- Pregnant or lactating
- Use of blood thinning medications
- Adherence to a weight loss program
- Allergy to fish
Key Trial Info
Start Date :
September 4 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2021
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT04088240
Start Date
September 4 2019
End Date
January 31 2021
Last Update
February 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Arizona
Tucson, Arizona, United States, 85721